Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top …

Nov 7, 2024 · Sarepta shares settled at $127.97 on Wednesday. See how other analysts view this stock . Leerink Partners raised Zymeworks Inc. ZYME price target from $10 to $25.

30%
OFF

Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top …

2 weeks from now

Nov 7, 2024 · Sarepta shares settled at $127.97 on Wednesday. See how other analysts view this stock . Leerink Partners raised Zymeworks Inc. ZYME price target from $10 to $25.

benzinga.com

30%
OFF

Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top …

2 weeks from now

Nov 7, 2024 · Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday. ... Cantor Fitzgerald raised the price target for Sarepta Therapeutics, Inc. …

webullfintech.com

30%
OFF

Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top …

2 weeks from now

Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday. Benzinga·11/07/2024 13:34:37. Listen to the news. Top Wall Street analysts changed their …

webull.com.sg

30%
OFF

Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top …

2 weeks from now

Nov 7, 2024 · TopWall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst …

futunn.com

30%
OFF

Latest News For Sarepta Therapeutics (NASDAQ:SRPT) Stock

2 weeks from now

Sarepta Therapeutics Stock (NASDAQ: SRPT) ... Here Are Top 5 Initiations For Monday. ... Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday.

benzinga.com

$158.87
OFF

A Glimpse Into The Expert Outlook On Sarepta Therapeutics

2 weeks from now

Dec 19, 2024 · Analysts have recently evaluated Sarepta Therapeutics and provided 12-month price targets. The average target is $158.87, accompanied by a high estimate of $205.00 and …

nasdaq.com

$182.77
OFF

26 Analysts Have This To Say About Sarepta Therapeutics

2 weeks from now

Jul 29, 2024 · Insights from analysts' 12-month price targets are revealed, presenting an average target of $182.77, a high estimate of $235.00, and a low estimate of $128.00.

nasdaq.com

4%
OFF

Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could …

2 weeks from now

Jul 19, 2024 · Sarepta Therapeutics (SRPT Quick Quote SRPT - Free Report) closed the last trading session at $143.78, gaining 16.4% over the past four weeks, but there could be plenty …

zacks.com

23%
OFF

SRPT Stock Rises 23% In A Year: Time To Buy, Hold Or Sell?

2 weeks from now

Jan 6, 2025 · Estimates for Sarepta Therapeutics’ 2024 earnings per share (EPS) have risen from $1.48 to $2.17 in the past 60 days. Over the same timeframe, EPS estimates for 2025 have …

zacks.com

30%
OFF

Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top …

2 weeks from now

Nov 7, 2024 · Cantor Fitzgerald raised the price target for Sarepta Therapeutics, Inc. SRPT from $152 to $167. Cantor Fitzgerald analyst Kristen Kluska upgradd the stock from Neutral to …

tradingview.com

2%
OFF

Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could …

2 weeks from now

Nov 27, 2024 · Shares of Sarepta Therapeutics (SRPT Quick Quote SRPT - Free Report) have gained 0.2% over the past four weeks to close the last trading session at $130.50, but there …

zacks.com

4%
OFF

Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could …

2 weeks from now

Oct 9, 2023 · Sarepta Therapeutics (SRPT) closed the last trading session at $123.94, gaining 3.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term …

yahoo.com

23%
OFF

SRPT Stock Rises 23% In A Year: Time To Buy, Hold Or Sell? - Yahoo …

2 weeks from now

Jan 6, 2025 · Shares of Sarepta Therapeutics SRPT have risen 23% in the past year, significantly outperforming the industry’s 15.7% decline, as shown in the chart below. During this …

yahoo.com

$176.93
OFF

Unveiling 15 Analyst Insights On Sarepta Therapeutics - Nasdaq

2 weeks from now

Oct 21, 2024 · Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $176.93, along with a high estimate of $205.00 and a low …

nasdaq.com

78%
OFF

After A Big Win, Is Sarepta Therapeutics Stock A Buy?

2 weeks from now

Jul 6, 2024 · On June 20, the Food and Drug Administration (FDA) gave Sarepta Therapeutics (SRPT-1.78%) exactly what it wanted. The agency upgraded the status of its gene therapy for …

fool.com

30%
OFF

Sarepta Therapeutics: Why Today's Rally On DMD Drug Label …

2 weeks from now

Jun 21, 2024 · Sarepta Therapeutics stock price soars over 30% to >$160 following the news, on potential for profitability and dominance in DMD gene therapy market. FDA approval for the …

seekingalpha.com

9%
OFF

Why Sarepta Therapeutics Shares Are Trading Higher By Around …

2 weeks from now

Jun 21, 2024 · VFS fell 7.9% to $3.97 in pre-market trading after gaining 10% on Thursday. Now Read This: Top 4 Consumer Stocks that May Keep You Up At Night This Month SRPT …

benzinga.com

$437
OFF

SRPT Finishes Enrolment In Late-Stage Study For Rare Muscular …

2 weeks from now

Dec 19, 2024 · Sarepta has added around $437 million in product sales in the first nine months of 2024. In comparison, the therapy generated more than $200 million in sales last year.

zacks.com

FAQs about Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top … Coupon?

Is Sarepta Therapeutics (SRPT) a good stock to buy?

Sarepta Therapeutics (SRPT) closed the last trading session at $123.94, gaining 3.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $186.65 indicates a 50.6% upside potential. ...

Will Sarepta Therapeutics (SRPT) see an upside potential?

The consensus price target hints at a 50.6% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. ...

Is Sarepta Therapeutics getting more data before prescribing it?

Sarepta Therapeutics just received expanded labeling for one of its therapies. But the therapy has not performed as well as expected in clinical trials. Some clinicians may prefer to wait for more data before prescribing it. One key issue remains unresolved, and it could be a significant one. ...

Could Sarepta's FDA approval be retracted?

And it's conceivable that one day the approval could be revised or retracted if Sarepta continues to fall short of the data that some of the FDA's review teams are seeking. Such an outcome would be a huge setback for Sarepta Therapeutics. ...

Why did Sarepta choose a Phase 3 trial?

But that view was superceded by the review committee, which ultimately went in Sarepta's favor. The confirmatory phase 3 trial, which then took place, was intended to demonstrate that the favorable early results were valid and reproducible, two standards that are key to biomedical science. ...

Why did Sarepta's stock surge?

The surge in the stock price can be attributed to the encouraging sales performance of Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys. Let’s delve into the company’s strengths and weaknesses to gain a better understanding of how to play the stock amid the price surge. ...